Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

Michiyo Higashi; Norishige Yamada; Seiya Yokoyama; Sho Kitamoto; Kazuhiro Tabata; Chihaya Koriyama; Surinder K. Batra; Suguru Yonezawa

doi:10.1159/000335164

Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

Michiyo Higashi, Norishige Yamada, Seiya Yokoyama, Sho Kitamoto, Kazuhiro Tabata, Chihaya Koriyama, Surinder K. Batra, Suguru Yonezawa

Research output: Contribution to journal › Article › peer-review

65 Scopus citations

Abstract

Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

Original language	English (US)
Pages (from-to)	101-106
Number of pages	6
Journal	Pathobiology
Volume	79
Issue number	2
DOIs	https://doi.org/10.1159/000335164
State	Published - Feb 2012

Keywords

CA125
Cholangiocarcinoma
MUC16
Prognosis

ASJC Scopus subject areas

Pathology and Forensic Medicine
Molecular Biology
Cell Biology

Access to Document

10.1159/000335164

Cite this

@article{96ebf23995b14d4cb9c2a5d55b974171,

title = "Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type",

abstract = "Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.",

keywords = "CA125, Cholangiocarcinoma, MUC16, Prognosis",

author = "Michiyo Higashi and Norishige Yamada and Seiya Yokoyama and Sho Kitamoto and Kazuhiro Tabata and Chihaya Koriyama and Batra, {Surinder K.} and Suguru Yonezawa",

year = "2012",

month = feb,

doi = "10.1159/000335164",

language = "English (US)",

volume = "79",

pages = "101--106",

journal = "Pathobiology",

issn = "1015-2008",

publisher = "S. Karger AG",

number = "2",

}

TY - JOUR

T1 - Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

AU - Higashi, Michiyo

AU - Yamada, Norishige

AU - Yokoyama, Seiya

AU - Kitamoto, Sho

AU - Tabata, Kazuhiro

AU - Koriyama, Chihaya

AU - Batra, Surinder K.

AU - Yonezawa, Suguru

PY - 2012/2

Y1 - 2012/2

N2 - Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

AB - Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-MF) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multivariate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion: The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF.

KW - CA125

KW - Cholangiocarcinoma

KW - MUC16

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84856175874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856175874&partnerID=8YFLogxK

U2 - 10.1159/000335164

DO - 10.1159/000335164

M3 - Article

C2 - 22286058

AN - SCOPUS:84856175874

SN - 1015-2008

VL - 79

SP - 101

EP - 106

JO - Pathobiology

JF - Pathobiology

IS - 2

ER -

Pathobiological implications of MUC16/CA125 expression in intrahepatic cholangiocarcinoma-mass forming type

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this